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Abstract
Background: We examined how extra-hepatic comorbidity burden impacts mortality in patients with cirrhosis
referred for liver transplantation (LT).
Methods: Adults with cirrhosis evaluated for their first LT in 2012 were followed through their clinical course with
last follow up in 2019. Extra-hepatic comorbidity burden was measured using the Charlson Comorbidity Index (CCI).
The endpoints were 90-day transplant free survival (Cox-Proportional Hazard regression), and overall mortality
(competing risk analysis).
Results: The study included 340 patients, mean age 56 ± 11, 63% male and MELD-Na 17.2 ± 6.6. The CCI was 0 (no
comorbidities) in 44%, 1–2 in 44% and > 2 (highest decile) in 12%, with no differences based on gender but higher
CCI in patients with fatty and cryptogenic liver disease. Thirty-three (10%) of 332 patients not receiving LT within
90 days died. Beyond MELD-Na, the CCI was independently associated with 90-day mortality (hazard ratio (HR), 1.32
(95% confidence interval (CI) 1.02–1.72). Ninety-day mortality was specifically increased with higher CCI category
and MELD ≥18 (12% (CCI = 0), 22% (CCI = 1–2) and 33% (CCI > 2), (p = 0.002)) but not MELD-Na ≤17. At last follow-
up, 69 patients were alive, 100 underwent LT and 171 died without LT. CCI was associated with increased overall
mortality in the competing risk analysis (Sub-HR 1.24, 95%CI 1.1–1.4).
Conclusions: Extra-hepatic comorbidity burden significantly impacts short-term mortality in patients with cirrhosis
and high MELD-Na. This has implications in determining urgency of LT and mortality models in cirrhosis and LT
waitlisting, especially with an ageing population with increasing prevalence of fatty liver disease.
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Background
Cirrhosis is a serious consequence of chronic liver dis-
eases, and represents a substantial burden of morbidity,
mortality and health-care expenditure. It carries a poor
prognosis in the setting of decompensation or develop-
ment of hepatocellular carcinoma, with liver transplant-
ation (LT) being the only definitive and lifesaving
therapy. In this context, extra-hepatic comorbidities may
carry multiple hazards to patients with cirrhosis in need
of LT. They carry direct risk of mortality related to the
impact of comorbidity [1, 2], as well as risk of precluding
candidacy for lifesaving LT [3], and even risk of post LT
mortality [4].
The Charlson Comorbidity Index (CCI) is a well de-
scribed and validated instrument determined by the
presence, and in some cases severity, of 16 comorbid
conditions, including liver disease [5]. The CCI predicts
1-year mortality in general populations and in patients
with organ specific disease such as acute and chronic
heart disease [5–8]. Both liver disease severity, reflected
in MELD, and HCC are known to impact mortality and
LT considerations in patients with cirrhosis. Beyond
MELD, CCI predicts mortality in patients with suspected
drug-induced liver injury [9]. However, the impact of
extra-hepatic comorbidity burden on short-term and
overall mortality in patients with advanced cirrhosis re-
ferred for LT has not been well-studied or quantified.
The assessment of overall comorbidity burden, rather
than individual comorbid conditions considered by
transplant centers, may provide an aggregate measure of
risk posed by the burden of extra-hepatic conditions.
In this study we measured the extra-hepatic medical
comorbidity burden in a cohort of consecutive patients
referred for LT using CCI (excluding the contributions
of liver disease and HCC). The aims of the study were to
determine the impact of extra-hepatic comorbidity bur-




This study was approved by the Indiana University insti-
tutional review board, and was performed and reported
per standardized reporting guidelines for qualitative re-
search [10]. All patients with cirrhosis evaluated for LT
at our center in 2012 were assessed. Patients were
followed from the time of initial assessment through
their pre and post-LT course until last follow-up in
2019. The selection of the study period was designed to
allow for a relatively long post-LT follow-up (anticipated
5 years or more).
Patients with prior LT, absence of cirrhosis, or referred
for multi-organ transplant were excluded. Demographic
and clinical data were collected, including age, gender,
body mass index (BMI), race, and etiology of liver dis-
ease. The severity of liver disease was measured using
the MELD sodium equation (MELD-Na) [11]. Patients
were followed until last contact for survivors or until
death.
Comorbidity burden
Extra-hepatic comorbidity burden was measured using
the CCI (contributions of liver disease and HCC to the
malignancy component were excluded). For example, a
patient with no extra-hepatic comorbidities but with cirrho-
sis and HCC would have a CCI of 0. The CCI was chosen
as an easily calculated and widely recognized comorbidity
score that is validated in multiple populations including pa-
tients with chronic and acute liver disease [5, 9, 12].
The CCI was analyzed primarily as a continuous vari-
able in all risk-models. In addition, to examine the im-
pact of low and high comorbidity burden we described
outcomes within CCI categories using the following two
thresholds; (i) patients with CCI = 0, a physiological ref-
erence group with the lowest extra-hepatic comorbidity
burden, and (ii) the highest decile of CCI (> 2 in this co-
hort) to reflect the impact of the highest comorbidity
burden. Patients with CCI = 1–2 represented an inter-
mediate comorbidity burden group.
Study endpoints
The cohort was followed through the LT evaluation
process with long-term follow up. The primary out-
comes were 90-day (short-term) mortality without LT
from the time of initial evaluation, which was examined
in patients not undergoing LT within 90-days. The sec-
ondary outcome was overall mortality (longer-term) with
LT as a competing risk, which was examined in all
patients.
Additional analyses
As a means of sensitivity testing for the association of
comorbidity burden with mortality, we repeated all ana-
lyses while measuring comorbidities with an alternate
score to CCI. The extra-hepatic comorbidity burden was
measured and analyzed using the Cirrhosis Comorbidity
score (CIRCOM), which has been validated in patients
with cirrhosis [2]. Both CCI and CIRCOM are validated
in patients with liver disease but they measure comor-
bidity burden somewhat differently. While CCI is a sim-
ple additive score, CIRCOM is designed as a conditional
model based on priority scores and variable inclusion of
specific groups of conditions. The individual comorbid
conditions and their relative weights in CCI and CIR-
COM are also not uniformly shared nor equally
weighted (Supplemental Table 1). We examined the as-
sociations of the two scoring systems and their
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component conditions with short and long-term mortal-
ity in this cohort.
Finally, we examined the impact of extrahepatic co-
morbidity burden on LT eligibility after excluding pa-
tients with obvious prohibitive conditions and those
deemed too early for or declining evaluation for LT.
Statistical methods
The analyses for factors associated with the study end-
points were performed using univariable and multivari-
able Cox proportional hazards regression for 90-day
mortality, and univariable and multivariable competing
risk regression for overall mortality, with LT as compet-
ing risk. The analyses were adjusted for age, gender,
BMI, race, etiology of liver disease, MELD-Na and HCC.
All analyses were two-sided with significance set at a p-
value< 0.05, and were performed using SPSS 26 (IBM
Corp. Released 2017. IBM SPSS Statistics for Windows,
Version 26.0. Armonk, NY: IBM Corp) or Stata SE 16
(StataCorp. 2019. Stata Statistical Software: Release 16.
College Station, TX: StataCorp LLC).
Results
Among the 387 patients evaluated for LT 47 were ex-
cluded, including 30 patients who were referred for
multi-organ transplant, 7 with prior LT and 10 without
underlying cirrhosis. The remaining 340 patients met
the inclusion criteria. Baseline demographic and clinic
characteristics are summarized in Table 1. The mean
CCI was 1 ± 1.2 and the median CCI was 1 (Interquartile
range (IQR) 0, 1), with a score distribution of 0 in 44%,
1 to 2 in 44%, and > 2 in 12% of patients. There were no
differences in mean CCI in females and males, although
females had a trend for higher frequency of connective
tissue disease (6.2% vs. 2.3%, (p = 0.06)). Mean CCI and
patient age differed significantly according to etiology of
cirrhosis (fatty liver (1.3 ± 1.1 and 61 ± 8), cryptogenic
(0.9 ± 1.4 and 62 ± 8), viral (1.1 ± 1.3 and 57 ± 8), alcohol
with viral (1.1 ± 1.4 and 54 ± 7), alcohol (0.6 ± 0.8 and
53 ± 10) and autoimmune (0.5 ± 1.1 and 51 ± 15) disease
(p = 0.003 and < 0.001), respectively). While CCI did not
correlate with patient age per se (Pearson coefficient
0.08, (p = 0.15)), mean age increased with higher CCI
category (55 ± 10 with CCI = 0, 56 ± 9 with CCI = 1–2
and 59 ± 7 with CCI > 2) (p = 0.025).
The impact of comorbidity burden on 90-day survival
Among the 340 patients evaluated 33 died within 90 days
without LT, while 8 underwent LT within 90-days and
were excluded from this specific analysis. Causes of
death included multiorgan failure (7), infection (4),
gastrointestinal bleed (4), cardiac (3), stroke (1) and un-
determined (14). The CCI was independently associated
with increased 90-day mortality on multivariable Cox
regression analysis (Table 2), as was MELD-Na. The fac-
tors not associated with 90-day mortality included age,
gender, BMI, race, etiology of liver disease and HCC.
The results were similar when excluding 7 patients with
moderate to severe renal disease (contributing to CCI)
which also contributed to higher MELD-Na. Extra-
hepatic comorbidity burden as measured by CIRCOM
was associated with an almost identical 90-day mortality
risk (adjusted HR 1.34, 95%CI 1.02–1.77).
On closer examination, the impact of CCI on 90-day
mortality was largely related to increasing risk in pa-
tients with MELD-Na above the median value of 17. In
patients with MELD-Na ≥ 18, 90-day mortality was 12%
with CCI = 0, 22% with CCI = 1–2 and 33% with CCI > 2,
(p = 0.03)). Whereas in patients with MELD-Na ≤ 17, 90-
day mortality was 1% with CCI = 0, 1% with CCI = 1–2
and 4% with CCI > 2, (p = 0.5)). Patients with MELD-
Na ≥ 18 also had increasing 90-day mortality with higher
categories of CIRCOM (11% with CIRCOM= 0, 18%
with CIRCOM= 1–2 and 39% with CIRCM> 2 (highest
decile for CIRCOM), (p = 0.002)).
The impact of comorbidity burden on overall survival
The median overall follow-up to time of death, LT or
last follow-up was 332 days (IQR 161, 919). During this
time 186 patient died with a median time to death of
303 days (IQR 126, 822). The median follow-up in 54 pa-
tients alive at last contact without LT was 6 years (IQR
0.6, 6.5), and in 100 patients who underwent LT was 5.7
years (IQR 4, 7.3). Post-LT patient and graft survival
rates were both 90% at 1 year and 81% at 5 years. Patients
who died without LT had higher comorbidity burden than
those who survived or underwent LT (Table 3). Compared
to surviving patients, they were also more commonly male
with viral liver disease, higher MELD-Na and HCC.
The CCI was associated with increased overall mortal-
ity on multivariable competing risk regression analysis
(Table 4). The risk-adjusted cumulative incidence of
mortality increased with each CCI point (Fig. 1). Extra-
hepatic comorbidity burden as measured by CIRCOM
was also associated with overall mortality (adjusted Sub-
HR 1.3, 95%CI 1.2–1.5). The CCI was associated with
overall mortality irrespective of baseline MELD-Na (ad-
justed sub-HR 1.3 (95%CI 1.1–1.6) with MELD-Na ≤ 17,
and adjusted sub-HR 1.2 (95%CI 1.1–1.4) with MELD-
Na ≥ 18).
Individual comorbidities versus comorbidity burden and
mortality
We examined the association of individual components
of the CCI and CIRCOM with 90-day and overall mor-
tality using univariable models due to small numbers of
patients with each condition (Table 5). Only renal dis-
ease defined by a creatinine≥1.5 mg/dL (included in
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CIRCOM and contributes to MELD-Na) was associated
with 90-day mortality. The conditions common to CCI
and CIRCOM that were associated with overall mortality
included congestive heart failure, renal disease and
metastatic malignancy. The conditions included in CCI,
but not CIRCOM, that were associated with overall mor-
tality included chronic obstructive pulmonary disease,
diabetes mellitus with complications, cerebrovascular
disease, connective tissue disease and acquired immune
deficiency syndrome. At least one of these conditions
was observed in 27.1% of patients. The condition in-
cluded in CIRCOM, but not CCI, that was associated
with overall mortality was substance abuse (excluding
alcohol) observed in 19.6% of patients.
The impact of comorbidity burden on liver transplant
eligibility
After the initial visit, 40 patients were deemed too early
for LT and 38 patients chose not to pursue LT, and did
not complete testing. Half of these patients were female,
with mean MELD < 15, mean CCI < 1, and < 10% had
HCC (Supplemental Table 2). Additionally, 48 patients
died before completing transplant evaluation and, 28 did
not complete evaluation. These patients were more fre-
quently male, with mean MELD> 15 and mean CCI > 1
(Supplemental Table 2). The most common barriers for
LT eligibility in patients attempting but not completing
LT evaluation were advanced HCC, morbid obesity and
active substance abuse which are not reflected in CCI,
Table 1 Baseline demographic and clinical characteristics of the 340 patients evaluated for liver transplantation for complications of
cirrhosis. Data are shown as mean ± standard deviation or percentage unless otherwise specified. Patients who died within 90-days













Age 56 ± 11 57 ± 9 56 ± 9 0.5
Gender (male) (%) 63 21 40 0.04
Race (%)
White 90 85 91 0.6
Black 5 9 4
Hispanic 3 6 3
Asian 1 None 1
Other 1 None 1
Body mass index 30 ± 7 30 ± 8 30 ± 6 0.7
Etiology of liver disease (%)
Alcohol 19 12 20 0.4
Alcohol and viral 16 24 16
Viral 32 39 31
Autoimmune 8 None 8
Fatty liver 21 21 21
Cryptogenic 2 3 2
MELD-Na 17.2 ± 6.6 25.1 ± 7.3 16.2 ± 5.8 < 0.001
Hepatocellular carcinoma (%) 24 30 23 0.4
CCI (mean) 1 ± 1.2 1.4 ± 1.2 1 ± 1.2 0.09
(median (IQR)) 1 (0,1) 1 (0, 2) 1 (0,1)
CCI category (%)
CCI = 0 44 30 46 0.07
CCI = 1–2 44 52 43
CCI > 2 12 18 110.
CIRCOM (mean) 0.8 ± 1.2 1.6 ± 1.4 0. ± 1.1 0.001
(median (IQR)) 0 (0,1) 1 (0, 3) 0 (0,1)
Abbreviations: CCI Charlson Comorbidity Index (excluding liver disease and liver cancer), IQR interquartile range, LT liver transplantation, MELD-Na Model for End-
stage Liver Disease with sodium modification
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although substance abuse is included in CIRCOM (Sup-
plemental Table 3).
One hundred and seventy-seven patients completed
the evaluation process and were discussed formally in
the transplant selection committee. They were predom-
inantly male (69%), with mean baseline MELD 17 ± 5.8,
mean CCI 0.98 ± 1.26, and 31% had HCC (Supplemental
Table 2). Of these 177 comprehensively evaluated pa-
tients 120 were approved for listing by the transplant se-
lection committee and 57 were deemed ineligible. The
CCI was inversely associated with LT eligibility in the
risk-adjusted model, whereas male gender and auto-
immune liver disease were associated with LT eligibility
(Table 6). Factors not associated with LT eligibility in-
cluded age, MELD, BMI, race, and HCC. Extra-hepatic
comorbidity burden was also inversely associated with
LT-eligibility in the risk-adjusted analysis when assessed
using CIRCOM (adjusted HR 0.74, 95%CI 0.6–0.91, p =
0.004).
The most common barriers to LT eligibility in the 57
patients were cardiac, advanced HCC, psychosocial con-
cerns and debilitation (Supplemental Table 3). Cardiac
factors prohibitive of LT in 16 patients were related to
coronary artery disease in 13 and uncontrolled arrhyth-
mias in 2, neither of which is reflected in CCI or CIR-
COM. The individual comorbid conditions that impacted
LT eligibility in the unadjusted analysis included coronary
artery disease without infarction, congestive heart failure,
peptic ulcer disease, diabetes with complication, renal dis-
ease and substance abuse (Supplemental Table 4). Only
120 patients were waitlisted of whom 100 underwent LT.
Both CCI and CIRCOM did not impact waitlist or post-
LT survival in the risk adjusted analyses, although the
number of patients analyzed was small (data not shown).
Discussion
The main novel finding in this study was that extra-
hepatic comorbidity burden adversely impacted 90-day
mortality among patients with cirrhosis evaluated for
LT. This interplay between CCI and MELD-Na for
short-term mortality was largely attributed to increased
risk in patients with MELD-Na ≥ 18. Interestingly, the
inflection threshold for improving survival benefit for
LT in cirrhosis was recently demonstrated at a MELD-
Na range of 18–20 [13]. In other words, extra-hepatic
comorbidity burden appears to amplify short-term mor-
tality in patients with cirrhosis who benefit the most
from LT, and may be an important consideration for LT
urgency in these patients.
The association of CCI and 90-day mortality persisted
even when excluding patients with moderate to severe
renal disease that may confound the association due to
contribution of creatinine to MELD-Na. Beyond renal
dysfunction, which is already reflected in higher MELD-
Table 2 The analysis of factors associated with 90-day mortality without liver transplant (LT) by Cox regression in 332 patients with
cirrhosis referred for LT, 33 of whom died within 90 days of initial evaluation. Eight of 340 patients assessed underwent LT within 90-
days from initial assessment and were excluded from this analysis
Factor Univariable analysis Multivariable analysis
Hazard ratio 95% confidence interval p-value Hazard ratio 95% confidence interval P-value
CCI 1.2 (0.97–1.5) 0.09 1.33 (1.02–1.73) 0.037
MELD-Na 1.22 (1.16–1.29) < 0.001 1.26 (1.18–1.33) < 0.001
Age 1.01 (0.98–1.06) 0.5 1.02 (0.96–1.07) 0.5
Male gender 2.4 (1.03–5.4) 0.043 1.2 (0.5–3) 0.6
Body mass index 1.01 (0.96–1.07) 0.4 1.02 (0.96–1.09) 0.4
Race (reference white)
Black 2.2 (0.7–7.1) 0.2 2.9 (0.8–11) 0.12
Hispanic 1.9 (0.5–7.9) 0.4 0.4 (0.1–1.7) 0.19
Asian NAa NAa
Etiology liver disease (Reference alcohol)
Alcohol and viral 2.4 (0.7–8) 0.15 2.8 (0.8–9.8) 0.08
Viral 1.9 (0.6–6) 0.24 2.3 (0.7–7.8) 0.15
Autoimmune NAa NAa
Fatty liver 1.6 (0.5–5.5) 0.4 3.3 (0.8–14.3) 0.11
Cryptogenic 2.1 (0.2–18.8) 0.5 2.6 (0.2–31) 0.5
Hepatocellular carcinoma 1.4 (0.7–2.9) 0.4 2 (0.8–5) 0.11
Abbreviations: CCI Charlson Comorbidity Index (excluding liver disease and liver cancer), MELD-Na Model for End-stage Liver Disease with sodium modification, NA
not applicable
Footnotes: a no patients in the analysis or with the endpoint to analyze
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Na, no component conditions of CCI or CIRCOM were
associated with 90-day mortality. Therefore, the overall
burden of extrahepatic comorbidities, as measured by
CCI or CIRCOM, rather than specific conditions were
the drivers of risk for 90-day mortality. This underscores
the potential utility of an aggregate comorbidity burden
score, beyond individual conditions, in risk assessment
for patients with advanced liver disease.
Liver transplantation was an important factor in the
consideration of overall mortality, with expected high
rates of patient survival at 5 years post LT. This necessi-
tated the assessment of overall mortality with competing-
risk regression as described by Fine and Gray [14]. Since
few patients underwent LT within 90-days of initial evalu-
ation the short-term mortality risk with CCI could not be
attributed to the impact of CCI on transplant eligibility.
However, comorbidities may represent barriers for LT
candidacy, and not surprisingly comorbidity burden was
higher in patient who died compared with those undergo-
ing LT or surviving without LT. This data suggests that
comorbidity may carry dual risks for patients with cirrho-
sis. An increased short-term risk in those with more ad-
vanced disease, and longer-term risk of both mortality and
potential barriers to life-saving LT as their liver disease
detriorates11–12%.
The examination of the impact of individual comorbid
conditions also demonstrated that no scoring system
captured all conditions that appeared to impact overall
mortality in the cohort. The CCI does not measure sub-
stance abuse which is included in CIRCOM, and CIR-
COM does not measure 5 conditions included in CCI
(chronic obstructive pulmonary disease, diabetes mellitus
Table 3 Baseline demographic and clinical characteristics of the patients evaluated for liver transplantation (LT) for complications of
cirrhosis among patients who; (i) were alive at last follow up without LT, (ii) died without LT or (iii) underwent LT. Data are shown as
mean ± standard deviation or percentage







Age 54 ± 10 57 ± 9 56 ± 10 0.14
Gender (male) (%) 43 64 71 0.002
Race (%)
White 87 91 91 0.4
Black 4 4 6
Hispanic 6 4 1
Asian None 1 1
Other 3 None 1
Body mass index 28 ± 6 30 ± 7 30 ± 6 0.4
Etiology of liver disease (%)
Alcohol 29 34 30 0.001
Alcohol and viral 12 21 10
Viral 29 18 13
Autoimmune 9 2 17
Fatty liver 19 20 24
Cryptogenic 2 2 3
MELD 13.9 ± 4.4 17.7 ± 7.1 18.1 ± 5.9 < 0.001
Hepatocellular carcinoma (%) 7 27 25 0.01
CCI (mean) 0.6 ± 0.9 1.1 ± 1.3 0.6 ± 0.8 < 0.001
(median (IQR)) 0 (IQR 0,1) 1 (IQR 0,2) 0 (IQR 0,1)
CCI Category (%)
CCI = 0 59 34 56 0.001
CCI = 1–2 33 50 38
CCI > 2 8 16 6







Abbreviations: CCI cirrhosis-modified Charlson Comorbidity Index (excluding liver disease and liver cancer), IQR interquartile range, MELD-Na Model for End-stage
Liver Disease with sodium modification
Footnotes: a includes one patient who underwent LT at another center
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Table 4 The factors associated with overall mortality in the competing-risk regression analysis with liver transplantation as the
competing risk
Factor Univariable analysis Multivariable analysis
Sub-Hazard ratio 95% confidence interval P-value Sub-Hazard ratio 95% confidence interval P-value
CCI 1.25 (1.14–1.38) < 0.001 1.24 (1.1–1.4) < 0.001
MELD-Na 1.05 (1.02–1.08) 0.002 1.05 (1.02–1.09) 0.001
Age 1.01 (0.99–1.02) 0.2 1.01 (0.99–1.03) 0.2
Male gender 1.2 (0.9–1.6) 0.3 0.94 (0.7–1.3) 0.7
Body mass index 1.01 (0.98–1.03) 0.5 1.01 (0.98–1.03) 0.7
Race (reference white)
Black 0.9 (0.5–1.7) 0.7 0.8 (0.4–1.7) 0.5
Hispanic 1.5 (0.7–3.3) ..3 1.4 (0.5–3.5) 0.6
Asian 1.3 (0.4–5) 0.7 3.1 (1.6–5.7) 0.001
Etiology liver disease (Reference alcohol)
Alcohol and viral 1.7 (1.02–2.7) 0.03 1.6 (0.96–2.67) 0.07
Viral 1.2 (0.8–1.8) 0.4 1.1 (0.7–1.8) 0.6
Autoimmune 0.2 (0.08–0.6) 0.006 0.2 (0.09–0.7) 0.009
Fatty liver 1.1 (0.7–1.7) 0.7 0.9 (0.6–1.6) 0.8
Cryptogenic 1.1 (0.5–2.7) 0.8 0.7 (0.4–2.2) 0.8
Hepatocellular carcinoma 1.3 (0.9–1.7) 0.14 1.1 (0.7–1.6) 0.7
Abbreviations: CCI Charlson Comorbidity Index (excluding liver disease and liver cancer), MELD-Na Model for End-stage Liver Disease with sodium modification, NA
not applicable
Fig. 1 Overall mortality in the competing risk model (liver transplant as the competing risk) stratified by comorbidity burden using the Charlson
Comorbidity Index (CCI) (excluding liver disease and liver cancer). The analysis was adjusted for age, gender, race, model for endstage liver
disease with sodium modification, body mass index, liver disease etiology and presence of hepatocellular carcinoma. The sub-hazard ratio for
each 1-point increment in CCI was 1.24 (95%confidence interval 1.1–1.4)
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with complications, cerebrovascular disease, connective
tissue disease and acquired immune deficiency syndrome).
These differences would have impacted comorbidity bur-
den measurement in 19.4 and 27.1% of patients, respect-
ively. Both scores still performed well as measures of
extra-hepatic comorbidity burden with very similar ad-
justed hazard and sub-hazard ratios. It is not within the
scope nor the intent of this study to suggest modifications
of comorbidity scoring systems, but we acknowledge the
interesting differences between these scores that could im-
pact 1 in 4 to 5 patients with advanced cirrhosis.
The CCI was developed as a continuous scale or vari-
able and the categorical descriptive analysis warrants dis-
cussion. A CCI = 0 reflects a physiologically important
reference group with no or very low comorbidity bur-
den. A CCI > 2 highlighted the risks associated with the
highest decile of extra-hepatic comorbidity burden, e.g.
in patients with higher MELD-Na. Notably, other studies
have demonstrated increased mortality in patients with
cardiac disease and in patients without cirrhosis present-
ing with acute liver injury, using the same threshold [9,
15, 16]. However, the ideal thresholds if any for estimat-
ing CCI related risk in the context of pre-LT outcomes
may be refined with additional studies.
A higher comorbidity burden was observed in patients
with fatty and cryptogenic liver disease. The latter is com-
monly attributed to undiagnosed fatty liver disease, which
is known to be associated with extra-hepatic comorbidities
and increasingly driving the need for LT in the United
Sates [17, 18]. While we observed age differences accord-
ing to disease etiology, extra-hepatic comorbidity burden
did not correlate with age per se, suggesting that the ob-
served associations were mainly related to differences in
disease associations rather than older age alone. Gender-
based disparities in LT eligibility have been described with
increased pre-LT and waitlist mortality in women [19, 20].
Additionally, gender-based differences in medical comor-
bidities have been described in hospitalized patients with
higher rates of diabetes and connective tissue disease but
without evident differences in hospital mortality [21]. In
our cohort, there were no gender-based differences in
CCI, although women had a trend for more frequent con-
nective tissue disease. Higher 90-day mortality was ob-
served in men, but that association was fully attenuated in
the risk-adjusted analysis.
In practice, LT candidate selection is impacted by indi-
vidual clinically relevant comorbidities and psychosocial
considerations rather than a comorbidity burden score
such as CCI. There is a dearth of data in this area, but
Arya et al. have demonstrated that less than half of pa-
tients evaluated for LT were deemed ineligible, mainly
for being too early, medical conditions or addiction
problems [3]. We observed similar outcomes in our co-
hort and explored the role of comorbid conditions in de-
tail as potential barriers to LT. Extra-hepatic comorbidity
burden (CCI) was associated with LT-ineligibility and
multiple comorbid conditions were individually associated
with LT-ineligibility. However, the majority of barriers to
Table 6 The factors associated with liver transplant (LT) eligibility by Cox regression analysis in 177 patients completing work-up for LT
Factor Univariable analysis Multivariable analysis
Hazard Ratio 95% confidence interval P-value Hazard Ratio 95% confidence interval P-value
CCI 0.64 (0.53–0.78) < 0.001 0.63 (0.51–0.79) < 0.001
MELD committee 0.99 (0.96–1.01) 0.2 1 (0.97–1.03) 0.96
Age 1.002 (0.98–1.025) 0.9 1 (0.97–1.03) 0.9
Male gender 1.3 (0.9–1.9) 0.16 2.3 (1.5–3.7) < 0.001
Body mass index 0.98 (0.96–1.01) 0.3 0.99 (0.96–1.03) 0.7
Race (reference white)
Black 0.71 (0.3–1.2) 0.4 1.1 (0.4–2.6) 0.9
Hispanic 1.2 (0.4–3.8) 0.8 1.8 (0.5–6.2) 0.4
Asian 4.6 (1.1–18.8) 0.036 2 (0.5–10.6) 0.4
Etiology of liver disease (Reference alcohol)
Alcohol and viral 0.7 (0.3–1.3) 0.2 0.6 (0.3–1.2) 0.16
Viral 1.1 (0.6–1.9) 0.8 1.1 (0.6–2.1) 0.7
Autoimmune 2.1 (1.1–4) 0.03 2.4 (1.2–5.2) 0.02
Fatty liver 1.1 (0.6–2) 0.9 1.6 (0.8–3.2) 0.17
Cryptogenic 1.2 (0.4–3.7) 0.7 0.9 (0.3–3.1) 0.9
Hepatocellular carcinoma 0.65 (0.43–0.98) 0.038 1 (0.6–1.7) 0.98
Abbreviations: CCI Charlson Comorbidity Index (excluding liver disease and liver cancer), MELD Model for End-stage Liver Disease with sodium modification, NA
not applicable
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LT in patients reviewed by the selection committee or in
those not completing evaluation (coronary artery disease,
obesity, being too ill or frail, advanced HCC or psycho-
social issues such substance abuse) were not reflected in
the CCI. Only 5 patients were LT-ineligible for other co-
morbidities (lung disease 2, and non-liver malignancy 3)
which were reflected in CCI. The CCI components of dia-
betes with end organ damage and peptic ulcer disease
were also associated with LT-ineligibility, but were not in
of themselves contraindications for LT. In other words,
conditions contraindicating LT were reflected in CCI in
less than 10% of LT-ineligible patients. Therefore, meas-
urement of extra-hepatic comorbidity burden was not a
substitute for, but possibly complementary of, reasoned
clinical judgment in determining LT candidacy.
The strengths of this study include the comprehensive
characterization of comorbid conditions and the long-
term follow up of patients with cirrhosis consecutively
evaluated for LT. The assessment of extra-hepatic comor-
bidity burden using two validated systems (CCI and CIR-
COM) and convergence of the observed associations also
support the clinical premise of the study. The limitations
of the study include the retrospective design, limited racial
diversity, the absence of comprehensive information on
socioeconomic status, and in some cases limited follow-up
intervals in patients not undergoing LT. Finally, the use of
CCI and CIRCOM in this study was demonstrative of the
impact of comorbidity burden on mortality and was not a
judgement of superiority of a specific score over other
available instruments.
Conclusion
In summary, this study demonstrates and quantifies the
risk associated with extra-hepatic comorbidity burden
with increased short and long-term mortality in patients
with advanced cirrhosis. These data are timely, given an
ageing population and increasing burden of fatty liver dis-
ease and comorbid conditions on transplant and other
healthcare resources. Assessment of comorbidity burden
may identify a subset of patients with the highest mortality
risk and increased LT urgency. If validated, standardized
measurement of extra-hepatic comorbidity burden may
also be an important modifier of mortality risk models
and mortality-related healthcare metrics in cirrhosis. Fur-
ther studies are needed to confirm these findings, and to
determine the ideal comorbidity scoring system and
thresholds in patients with advanced cirrhosis.
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